Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

ojected cash flows accruing to Elan from the Pre-Restructuring Tysabri Participation (before the completion of the Tysabri Transaction) and the residual Tysabri Royalty (after the completion of the Tysabri Transaction).

Royalty Pharma has prepared an illustrative calculation which assumes that the Disposed Tysabri Percentage is between 46 percent and 54 percent (the "Disposed Tysabri Percentage Range"). This illustrative calculation was prepared solely based upon Royalty Pharma's analysis of the terms of the Tysabri Transaction and publicly available forecasts for Tysabri. Biogen paid US$3.25 billion for the Disposed Tysabri Interest.

Based on the Disposed Tysabri Percentage Range and Royalty Pharma's assumptions, the Tysabri Transaction ascribed a value of between US$2.77 billion and US$3.81 billion to the residual Tysabri Royalty. Using the mid-point of the Disposed Tysabri Percentage Range of 50 percent would indicate that the Tysabri Transaction ascribed a value of US$3.25 billion to the residual Tysabri Royalty. The Proposal Enterprise Value of US$3.56 billion[18] represents a 9.6 percent premium to this value.

In its calculations above, Royalty Pharma makes no adjustment for the value of synergies that may be realized by Biogen. Biogen has stated that its annual operating synergies from the Tysabri Transaction will be approximately US$30 million[19]. No other buyer could have realized such synergies and no further similar synergies are now available.

Royalty Pharma believes that these synergies can be viewed as reducing the effective net cost to Biogen. As such, Royalty Pharma believes that its calculation may over-state the value ascribed by the Tysabri Transaction to the standalone value of the Disposed Tysabri Interest, and by implication may over-state the value of the residual Tysabri Royalty.

In its calculation, Royalty Pharma ascribes minimal value to Elan's non-cash assets other than to the residual Tysabri Royalty.
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... LA (PRWEB) August 01, 2014 Chantel Lee ... conduct research for 10 40-hour weeks with Dr. Juan Rodriguez, ... of diabetic retinopathy, a common diabetic eye disease caused by ... , "What Chantel and Eli accomplished is quite remarkable,” said ... only a concept when they started, and together carried it ...
(Date:8/1/2014)... As one of the 10 largest medical ... & Clinical Lab Expo is the place where breakthrough ... to the healthcare world. This year, many of the ... include the latest diagnostic technology in the field of ... biosensors have enabled the development of "labs-on-a-chip" that can ...
(Date:8/1/2014)... 1, 2014 Research and Markets ... Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism (SNP) genotyping ... SNPs in the genome of various species. SNPs are ... and analysis technology can analyze thousands of SNPs and ...
(Date:8/1/2014)... August 01, 2014 Testing the ... to a better understanding embryonic development. How ... into structurally and functionally distinct tissues is important ... Prof. Todd McDevitt, Melissa Kinney, and Rabbia ... interact with biochemical cues to control many aspects ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a pharmaceutical ... and commercialization,of a broad range of prescription and ... the following statement regarding the earthquake in,China:, ... China,s earthquake and we,are thankful to report that ...
... EAST RUTHERFORD, N.J., May 15 Cambrex (NYSE:,CBM), a ... of,Directors appointed Steven M. Klosk, President and Chief Executive ... Directors effective May,14, 2008. James A. Mack, President and ... announced he will step down. The Company will,separate the ...
... PRINCETON, N.J., May 15 Derma Sciences, Inc.,(OTC ... results today for the first quarter ended March 31, ... the previous year, including sales,from the newly acquired First ... guidance, due primarily to higher than expected,integration costs associated ...
Cached Biology Technology:American Oriental Bioengineering Comments on Earthquake 2Cambrex Appoints Steven M. Klosk as President and CEO 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5
(Date:7/31/2014)... the largest minority group in the United States, comprising ... are obese and are 1.2 times as likely to ... College of Nursing student researcher Lauren Gerchow, BSN, RN, ... contribute to this problem by compiling a systematic review ... Latina women recently published in Nursing Research . ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... COLUMBUS , Ohio -- As sea levels rise, coastal communities ... water supplies than previously thought, according to a new study ... saltwater will intrude into fresh water aquifers, given the sea ... (IPCC). The IPCC has concluded that within the next 100 ...
... In a recent academic review, a University of Minnesota professor ... as opposed to specific nutrients, may be key to having ... practice in food industry and government, where marketers and regulators ... on specific vitamins and added supplements in food products, not ...
... produce lubricin, a thin film of protein found in ... friction in their joints, a new study led by ... friction and early wear in joints is a first; ... before. The finding, published in Arthritis & Rheumatism, sheds ...
Cached Biology News:Climate change could diminish drinking water more than expected 2Climate change could diminish drinking water more than expected 3Foods, not specific nutrients, may be key to good health 2First-ever study: lack of critical lubricant causes wear in joints 2
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: